Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cleveland Clinic's Top 10 Medical Innovations For 2009

This article was originally published in The Gray Sheet

Executive Summary

1. Use of circulating tumor cell technology: A blood test assessing chemotherapy progress by measuring for cancer cells that have broken away from an existing tumor and entered the bloodstream.

You may also be interested in...



Synapse Biomedical Debuts Diaphragm Pacer, HDE-Cleared To Aid Breathing

Synapse Biomedical will pursue expanded approval of its diaphragm pacing system to facilitate breathing in patients with Lou Gehrig's disease after gaining a humanitarian device exemption June 17 for use by ventilator-dependent spinal cord injury patients, according to the company

Funding Doubles Women’s Health Firm Perelel’s Support, Boosts Odyssey Elixir Energy Visibility

Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.

Clinical Trial Reporting: US FDA To Step Up Listings, But Not Fines, After Petition

Following request by Universities Allied for Essential Medicines, FDA creates a public dashboard of pre-notices of noncompliance on registering trials and submitting results to ClinicalTrials.gov. The agency denies request to impose civil penalties on those who fail to comply, citing its discretion.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel